Anti-fibrotics in RA-ILD Retro analysis of 74 pts AEs frequent 55% and discontinuation in 46% (more than in initial RCTs) No diff between AF FCV trajectory mildly improved ABST2479 @RheumNow @Juge_P_A @PhilippeDieude #ACR23 https://t.co/GqsHxkIFgD

Rashes in Rheumatology at #ACR23 Which disease entity are these palms pathognomonic for? @RheumNow https://t.co/NmT1LTzWmm

Therapeutic Ladder for Discoid Lupus: 1. Strict🌞protection, smoking avoidance 2. Antimalarials 3. Topicals/intralesional corticosteroids, topical CNI 4. Oral steroids, retinoids, MTX, MMF 5. Thalidomide, lenalidomide 6. IVIG, JAKi, Belimumab... BUT also Anifrolumab!… https://t.co/xSw0s12Uvk https://t.co/stIJ944d9A

#ACR23 Abstr# 2485 Belimumab therapy in RCT was associated with increased risk of psychiatric events inc suicidality vs PBO. When compared with standard immunosuppressant, real-world data using emulated trial design showed no increased risk @RheumNow https://t.co/Vqhc5yRsSA

A new innovative way of teaching MS ultrasound to students using teledidactic teaching with portable ultrasound devices resulted in a significant increase in knowledge comparable to the conventional course, Schäfer SV, Abst#2079 #ACR23 @RheumNow https://t.co/re0gErx5ke https://t.co/yPbS9Rj0az

Late breaking at #ACR23: extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms Another six months with a crossover - & sustained symptomatic benefit after cessation. Fascinating, addresses a desperate clinical need, bring on the phase 3! ABSTL10 @RheumNow https://t.co/zUfnGEZefj https://t.co/S3lLwhwl85

Complements & HCQ? (Prof Petri et al) Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole blood levels >50 ng/mL Increasing blood levels of HCQ significantly assocd w/⬆️prob of achieving normal C4 Improving C3,C4; addtl benefit of HCQ? #ACR23 ABST2327 @RheumNow https://t.co/5ucpXq9ngb

#ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#SLE, #sjogren, MCTD, UCTD) & arthritis were homogenous related to clinical features, PROs & gene expression score. Offer rationale for basket trial @RheumNow https://t.co/7HTMxE7mSP

HCQ discontinuation in SLE? Why?! In this retro cohort of 42 pts Reasons: Retinal toxicity (57%) Self-discontinuation (17%) Factors strongly assoc'd w/ flares 1 yr after discontinuation - mean C3 and +dsDNA at index visit. #ACR23 ABST2343 @RheumNow https://t.co/BCO9N4gSkX

Im usually super shy on camera but my hair looks great in this video with my friend @RHEUMarampa as we talk about how our reviewer went from a personal project to a fellow study resource. #ACR23 #ACRambassador @RheumNow @cerego https://t.co/KHDni7epFK

Pain experience in #OA may have different contributing factors Its a while joint disease! What are the future targets in #OA being tested? @RheumNow #ACR23 @Tuhina_Neogi https://t.co/lI06pJrdYR

GCs on MACE in RA in VA A#2430 #ACR23 @RheumNow Not just ongoing steroid usage, also prior usage 1 year ago 5 mg use for 30 days one year ago - increases MACE events by 3% 5 mg use for 90 days one year ago - increases MACE events by 9%

Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o

Even low doses of steroids associated with major adverse cardiovascular events! Large VA database - >18k RA pts Dose as low as 5mg/day prednisone for 30 days, 1 year prior to event, associated with increased MACE @RheumNow #ACR23 Abs#2430 https://t.co/JjeoBi7YTD

Mok et al. Romosozumab superior to denosumab in high risk GIO. Superior in improving spine BMD. Not fracture. Fracture is what matters. Abstr#2429 #ACR23 @RheumNow https://t.co/5ModHOGsED